421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials
comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.
Authors
- D. Hu
- N. Yang
- K. Ma
- Q. Zhang
- J. Huang
- F. Zeng
Institutions
- Guangxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Second People Hospital of Hunan (CN)
- Hunan Cancer Hospital (CN)
- Roche (China) (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106735
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00